Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


FDA updates LDL-C lowering indication for Nexletol (bempedoic acid) tablet and Nexlizet (bempedoic acid and ezetimibe) tablet – Esperion

Written by | 2 Jan 2024 | Cardiology

Esperion announced that the FDA has approved an updated LDL-cholesterol lowering indication for Nexletol and Nexlizet to include the treatment of primary hyperlipidemia as a qualifier for existing approved populations .

Additionally, the maximally tolerated qualifier for statin use has been removed, and the prior limitation of use stating “the effect of Nexlizet or Nexletol on cardiovascular morbidity and mortality has not been determined” has also been removed .This update is effective immediately and is the result of the FDA’s efforts to modernize and synchronize drug labels, as well as Esperion’s commitment to expanding the indications for Nexletol and Nexlizet. “We are pleased that the FDA has approved these modifications to our current indications for Nexletol and Nexlizet, which reinforce the proven efficacy and safety of these treatments,” said Sheldon Koenig, President and CEO.

These labeling modifications do not impact the full pending label approvals for cardiovascular risk reduction indications for Nexletol and Nexlizet, which remain on track for anticipated approval in the first quarter of 2024. In June 2023, the Company announced its submission of four Supplemental New Drug Applications based on the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial, which demonstrated that bempedoic acid, contained in both Nexletol and Nexlizet, can significantly reduce cardiovascular risk across a range of primary and second endpoints. These applications were accepted by the FDA which issued a PDUFA, or action, date of March 31, 2024. The Company’s EMA applications also remain on track, with anticipated approval in the first half of 2024.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.